Zorbtive or serostim Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The zorbtive or serostim market research report is one of a series of new reports that provides zorbtive or serostim market statistics, including zorbtive or serostim industry global market size, regional shares, competitors with a zorbtive or serostim market share, detailed zorbtive or serostim market segments, market trends and opportunities, and any further data you may need to thrive in the zorbtive or serostim industry. This zorbtive or serostim market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to the rise in telemedicine platforms, the rise in demand for personalized and targeted treatments, the growth in research and development efforts, the surge in the aging population, and the increase in the prevalence of growth hormone deficiencies. Major trends in the forecast period include a shift towards precision medicine in hormone therapy, the use of home-based injection devices for patient convenience, the popularity of biosimilars as cost-effective alternatives, advancements in drug delivery technologies, and the expansion of market presence in emerging economies.

The rising number of patients with HIV is expected to drive the growth of the Zorbtive or Serostim market in the future. HIV is a virus that weakens the immune system by targeting CD4 cells, which are crucial for defending the body against infections. The increasing prevalence of HIV can be attributed to factors such as unprotected sexual activity, limited access to preventive healthcare, inadequate awareness and education, and difficulties in HIV testing and treatment, especially in high-risk populations. Zorbtive or Serostim addresses HIV-associated wasting syndrome by promoting weight gain, increasing lean body mass, and improving physical function and quality of life for patients with weakened immune systems due to the virus. For example, in April 2024, the Centers for Disease Control and Prevention (CDC) reported that approximately 31,800 new HIV infections occurred in the U.S. in 2022, with a significant portion of these cases among gay, bisexual, and other men who reported male-to-male sexual contact. This rising number of HIV patients is contributing to the growth of the Zorbtive or Serostim market.

The increasing focus on personalized treatments is also expected to fuel the growth of the Zorbtive or Serostim market. Personalized medicine tailors therapy to an individual's genetic, environmental, and lifestyle factors to improve treatment outcomes. Advancements in genetic research, better diagnostic tools, and a growing demand for more effective, targeted therapies are driving the rise in personalized treatments. Zorbtive or Serostim fits into this trend by offering a personalized approach to managing HIV-associated wasting syndrome. It helps promote weight gain, increases lean body mass, and enhances physical function, addressing the specific needs of patients with compromised immune systems due to HIV while improving their quality of life. For instance, the Personalized Medicine Coalition reported in February 2023 that personalized medicines accounted for 34% of new drug approvals by the U.S. FDA in 2022 and have consistently made up at least 25% of approvals over the past eight years. This growing emphasis on personalized medicine is likely to drive the Zorbtive or Serostim market.

The overall increase in healthcare spending and investment is expected to further support the growth of the Zorbtive or Serostim market. Healthcare spending refers to the financial resources allocated to healthcare services, infrastructure, research, and innovations that aim to improve public health. Rising healthcare expenditure is driven by factors such as an aging population, the growing prevalence of chronic diseases, advancements in medical technology, and the increasing demand for better healthcare. This rise in healthcare spending helps support the Zorbtive or Serostim market by funding research, improving treatment access, and ensuring insurance coverage for patients with HIV-associated wasting syndrome. For example, in May 2024, the Office for National Statistics in the UK reported that total healthcare expenditure reached approximately $366 billion, reflecting a 5.6% increase from the previous year, with much of this funding coming from government sources. This increase in healthcare spending is expected to continue driving the growth of the Zorbtive or Serostim market.

The key company operating in the zorbtive or serostim market is EMD Serono Inc.

North America was the largest region in the zorbtive or serostim market in 2024. The regions covered in zorbtive or serostim report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the zorbtive or serostim market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Zorbtive and Serostim are both recombinant human growth hormone therapies designed to treat growth hormone deficiency, particularly in patients with conditions such as AIDS-related wasting or severe short stature. These therapies stimulate growth, enhance protein synthesis, and improve overall body composition by increasing lean muscle mass and reducing fat.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary indications for Zorbtive and Serostim include short bowel syndrome and HIV-associated wasting. Short bowel syndrome (SBS) is a condition where the body is unable to absorb enough nutrients due to a shortened or compromised small intestine. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used by adult and geriatric patients.

The zorbtive or serostim market consists of sales of recombinant human growth hormone products, diagnostic kits, specialty medications, and nutritional and support products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.